Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →BioCentury reported the partnership terms — $60M upfront, up to $4B in milestones — and the geographic rights split with NJCTTQ taking China and Thailand,…
FierceBiotech ranked the NJCTTQ-Abpro deal #4 among 2019's top 15 biopharma licensing deals, calling it 'remarkable not only for its value but also because the…
Five years after the NJCTTQ deal, Abpro pursued a SPAC merger to return to Nasdaq and fund bispecific R&D — implying the NJCTTQ partnership had not generated…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Abpro and NJCTTQ entered a partnership to co-develop multiple novel bispecific T-cell engager antibodies in immuno-oncology using Abpro's DiversImmune platform. Abpro is eligible for up to $4B including $60M in near-term R&D funding plus milestones and royalties. NJCTTQ retained China/Thailand rights; Abpro retained ex-Greater China rights.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| NJCTTQ (Nanjing CTTQ Pharma) / Abpro Corporation (this deal) | 2019 | $4.0B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2019 deals · Oncology deals